NASH Stocks
Biopharmaceutical and diagnostic firms in this cohort target Non-Alcoholic Steatohepatitis (NASH), a chronic metabolic liver disease driven by the global obesity epidemic and insulin resistance.
As of Oct 23, 2026, NASH has 10 US-listed companies worth $187B combined. The median member moved +0.9% over the past week; IVA led at +26.2% and LPCN trailed at -7.7%.
Companies in NASH
- NVO – Novo Nordisk A/S, $172B
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- VKTX – Viking Therapeutics Inc, $3.1B
- IVA – Inventiva Sa, $770M
- SGMT – Sagimet Biosciences Inc. Series A Common Stock, $633M
- ALT – Altimmune Inc, $595M
- LPCN – Lipocine Inc, $16.9M
- NDRA – ENDRA Life Sciences Inc, $9.1M
- GLMD – Galmed Pharmaceuticals Ltd, $4.9M
- EOCN – Eocene Ltd., $3.8M